Product Categories
| Country: | China |
|---|---|
| Tel: | 177-54423994 |
| Mobile: | 17754423994 |
| E-mail: | 2853530910@QQ.com |
| QQ: | 2853530910 |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Icrucumab | 1024603-92-6 | Details |
| Fulranumab | 902141-80-4 | Details |
| Etrolizumab | 1044758-60-2 | Details |
| Enokizumab | 909875-08-7 | Details |
| Enavatuzumab | 1062149-33-0 | Details |
| Carlumab | 915404-94-3 | Details |
| Atinumab | 1226761-65-4 | Details |
| Samalizumab | 1073059-33-2 | Details |
| Ozoralizumab | 1167985-17-2 | Details |
| Pateclizumab | 1202526-59-7 | Details |
| Sirukumab | 1194585-53-9 | Details |
| Biotinyl Cystamine | C14H26N4O2S3 | 128915-82-2 | Details |
| AMG-131 | C21H12Cl4N2O3S | 315224-26-1 | Details |
| 2,4-Dichlorophenoxyacetyl chloride | C8H5Cl3O2 | 774-74-3 | Details |
| NCGC00378430 | C22H23N3O5S | 920650-00-6 | Details |
| Apostatin-1 | C19H27N3OS | 2559703-06-7 | Details |
| NCC007 | C22H28F3N7 | 2342583-66-6 | Details |
| AZ32 | C20H16N4O | 2288709-96-4 | Details |
| Urelumab | 934823-49-1 | Details |
| Ublituximab | 1174014-05-1 | Details |
| Tregalizumab | 1207446-68-1 | Details |
| Radretumab | 1253180-81-2 | Details |
| Dectrekumab | 1528523-94-5 | Details |
| Nemolizumab | 1476039-58-3 | Details |
| Isatuximab | 1461640-62-9 | Details |
| Vandortuzumab Vedotin | 1471985-92-8 | Details |
| Evinacumab | 1446419-85-7 | Details |
| Lokivetmab | 1533403-95-0 | Details |
| Tafasitamab | 1422527-84-1 | Details |
| Lacutamab | 2187368-16-5 | Details |
| Amivantamab | 2171511-58-1 | Details |
| Indusatumab Vedotin | 1514889-12-3 | Details |
| Andecaliximab | 1518996-49-0 | Details |
| SUC-ALA-ALA-PRO-PHE-PNA | C30H34N6O8 | 107409-54-1 | Details |
| Mc-Val-Ala-PAB-PNP | C32H37N5O10 | 1639939-40-4 | Details |
| YTX-465 | C25H26N6O3 | 2225824-53-1 | Details |
| SCD1 inhibitor-3 | C19H16FN7O2 | 1282606-48-7 | Details |
| ML339 | C26H32ClN3O5 | 2579689-83-9 | Details |
| Bocidelpar | C25H27F3N2O3 | 2095128-20-2 | Details |
| SR1664 | C33H29N3O5 | 1338259-05-4 | Details |
| RY785 | C21H20N4O2S | 1393748-80-5 | Details |
| JYN42346 | C27H24BrN7O3 | 1903742-34-6 | Details |
| AZD-1940 | C20H29F2N3O2S | 881413-29-2 | Details |
| INE963 | C19H26N6O2S | 2640567-43-5 | Details |
| GI 181771 | C34H31N5O6 | 305366-98-7 | Details |
| (R)-GSK-3685032 | C22H24N6OS | 2170140-50-6 | Details |
| Lirilumab | 1000676-41-4 | Details |
| Tesidolumab | 1531594-08-7 | Details |
| Ponezumab | 1178862-65-1 | Details |
| Onartuzumab | 1133766-06-9 | Details |
| Patritumab | 1262787-83-6 | Details |
| Quilizumab | 1228538-47-3 | Details |
| Solitomab | 1005198-65-1 | Details |
| Flanvotumab | 1188277-05-5 | Details |
| Inclacumab | 1256258-86-2 | Details |
| Caplacizumab | 915810-67-2 | Details |
| Indatuximab Ravtansine | 1238517-16-2 | Details |
| Vatelizumab | 1238217-55-4 | Details |
| Tabalumab | 1143503-67-6 | Details |
| Narnatumab | 1188275-92-4 | Details |
| Ficlatuzumab | 1174900-84-5 | Details |
| Crenezumab | 1095207-05-8 | Details |
| Blosozumab | 1132758-87-2 | Details |
| Vesencumab | 1205533-60-3 | Details |
| Fasinumab | 1190239-42-9 | Details |
| Enoticumab | 1192578-27-0 | Details |
| Duligotuzumab | 1314238-96-4 | Details |
| Demcizumab | 1243262-17-0 | Details |
| Clazakizumab | 1236278-28-6 | Details |
| Bezlotoxumab | 1246264-45-8 | Details |
| Actoxumab | 1245634-25-6 | Details |
| Futuximab | 1310460-85-5 | Details |
| Imgatuzumab | 959963-46-3 | Details |
| Ligelizumab | 1322627-61-1 | Details |
| JQKD-82 | C27H40N4O5 | 2410512-38-6 | Details |
| BioE-1197 | C20H18FN3O2 | 1268863-69-9 | Details |
| Zunsemetinib | C25H22ClF2N5O3 | 1640282-42-3 | Details |
| FTO-IN-3 | C12H10N4OS | 2585198-87-2 | Details |
| 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione | C10H11F3N2O5 | 1380532-27-3 | Details |
| SBI-425 | C13H12ClN3O4S | 1451272-71-1 | Details |
| YM150 | C27H30N4O4 | 365462-23-3 | Details |
| Ro60-0175 | C11H12ClFN2 | 169675-08-5 | Details |
| 2,4-Imidazolidinedione, 5-[3-[[4-[(3-methylphenyl)methoxy]phenyl]thio]-2-furanyl]- | C21H18N2O4S | 877176-23-3 | Details |
| OTX 008 | C52H72N8O8 | 286936-40-1 | Details |
| MRTX1719 | C23H18ClFN6O2 | 2630904-45-7 | Details |
| TH5427 | C20H20Cl2N8O3 | 2253744-56-6 | Details |
| Sigma-1 receptor antagonist 2 | C20H26ClN3O2 | 1639220-15-7 | Details |
| GSK251 | C29H37FN6O4S | 2125968-05-8 | Details |
| Erucin | C6H11NS2 | 4430-36-8 | Details |
| Ensitrelvir fumarate | C22H17ClF3N9O2.C4H4O4 | 2757470-18-9 | Details |
| Boc-Val-Ala-PAB-PNP | C27H34N4O9 | 1884578-00-0 | Details |
| 1-Piperidinamine, N-hydroxy-N-nitroso- | C5H11N3O2 | 56329-24-9 | Details |
| Tamtuvetmab | 1608122-71-9 | Details |
| Blontuvetmab | 1608112-78-2 | Details |
| Mirvetuximab | 1453084-36-0 | Details |
| Refanezumab | 1233953-61-1 | Details |
| Enoblituzumab | 1353485-38-7 | Details |
| Xentuzumab | 1417158-65-6 | Details |
| Cabiralizumab | 1613144-80-1 | Details |
| Satralizumab | 1535963-91-7 | Details |
| Product Total： Product Page： | ||||
| 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 | ||||